Synthesis, powder diffraction pattern, crystal structure determination of the pharmaceutical co-crystal of levetiracetam and 3,5-dinitrosalicylic acid
Source abstract
Abstract
( S )-α-Ethyl-2-oxo-1-pyrrolidineacetamide (trade name levetiracetam), a derivative of piracetam, is used clinically as an add-on treatment for partial-onset seizures. In this study, we report the solid-state structure of a new drug co-crystal produced from levetiracetam and 3,5-dinitrosalicylic acid through cooling crystallization. This compound was further characterized by infrared spectroscopy, powder X-ray diffraction, and single-crystal X-ray diffraction. The new co-crystals show a 1:1 stoichiometry and crystallize in the monoclinic system, space group P 2 1 , with cell parameters: a = 9.7709(3) Å, b = 6.2202(2) Å, c = 14.7280(4) Å, α = 90°, β = 96.0340(10)°, γ = 90°, V = 890.16(5) Å 3 , and Z = 2. It is identified that hydrogen bonds are the main interactions between levetiracetam and 3,5-dinitrosalicylic acid, and the contribution of each hydrogen bond in maintaining the stability of the crystal structure was also quantified using Hirshfeld surface analysis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · X-ray Diffraction in Crystallography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (28)
Show source-provided references
1. 10.1021/cg800764n10.1021/cg800764n ↗
2. 10.1021/acs.cgd.9b0013610.1021/acs.cgd.9b00136 ↗
3. 10.1016/j.drudis.2016.12.00110.1016/j.drudis.2016.12.001 ↗
4. 10.15171/bi.2018.3310.15171/bi.2018.33 ↗
5. 10.1016/j.ijpharm.2015.03.01210.1016/j.ijpharm.2015.03.012 ↗
6. 10.1016/j.inoche.2009.07.00210.1016/j.inoche.2009.07.002 ↗
7. 10.1208/s12249-017-0727-z10.1208/s12249-017-0727-z ↗
8. 2021
9. 10.1016/j.ijpharm.2014.12.03710.1016/j.ijpharm.2014.12.037 ↗
10. 10.1039/B203191B10.1039/B203191B ↗
11. 10.1107/S205252061500270X10.1107/S205252061500270X ↗
12. 10.1016/j.molstruc.2016.12.01910.1016/j.molstruc.2016.12.019 ↗
13. 10.1016/j.cplett.2011.03.03310.1016/j.cplett.2011.03.033 ↗
14. 10.1039/B818330A10.1039/B818330A ↗
15. 10.1016/S1359-6446(03)02832-010.1016/S1359-6446(03)02832-0 ↗
16. 10.1039/B9NJ00463G10.1039/B9NJ00463G ↗
17. 10.1016/j.jfluchem.2014.04.00210.1016/j.jfluchem.2014.04.002 ↗
18. 10.1016/j.molstruc.2011.06.00310.1016/j.molstruc.2011.06.003 ↗
19. 10.1007/s40263-015-0248-910.1007/s40263-015-0248-9 ↗
20. 10.1021/acs.molpharmaceut.8b0006110.1021/acs.molpharmaceut.8b00061 ↗
21. 10.1107/S205252061401171810.1107/S2052520614011718 ↗
22. 10.1007/s11095-017-2309-x10.1007/s11095-017-2309-x ↗
23. 10.1016/j.molstruc.2016.10.04410.1016/j.molstruc.2016.10.044 ↗
24. 10.1039/C6CC02943D10.1039/C6CC02943D ↗
25. 10.1021/acs.cgd.6b0142510.1021/acs.cgd.6b01425 ↗
26. 10.4314/tjpr.v16i2.610.4314/tjpr.v16i2.6 ↗
27. The Antiepileptic Drug Levetiracetam
28. 10.1107/S160057672100291010.1107/S1600576721002910 ↗